Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis
Authors:
- Chris AndersonCAChris Anderson
- Kjell HersleKHKjell Hersle
- Eva HradilEHEva Hradil
- Peter NordinPNPeter Nordin
- Taavi KaamanTKTaavi Kaaman
- Lars MolinLMLars Molin
- Arne PetterssonAPArne Pettersson
- 1 May 1995
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 32 (5) , 750-753
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Levels of terbinafine in plasma, stratum corneum, dermis/epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks.Acta Dermato-Venereologica, 1993
- A randomized treatment duration-finding study of terbinafine in onychomycosisBritish Journal of Dermatology, 1992
- Efficacy and safety of itraconazole in the long-term treatment of onychomycosisJournal of Antimicrobial Chemotherapy, 1992
- In vitro activity of terbinafineClinical and Experimental Dermatology, 1989
- The mechanism of action of terbinafineClinical and Experimental Dermatology, 1989
- Clinical pharmacokinetics of terbinafine (Lamisil)Clinical and Experimental Dermatology, 1989
- The topical treatment of onychomycosis using a new combined urea/imidazole preparationClinical and Experimental Dermatology, 1988
- Allylamine Derivatives: New Class of Synthetic Antifungal Agents Inhibiting Fungal Squalene EpoxidaseScience, 1984